Benabdallah Sebbagh R, Del Pozo Prieto D, Beceiro Pedreño I, Trueba Collado C, Salinas Núñez FM, González Sánchez-Ocaña L, Castellano López A, Tabernero da Veiga S. Pneumatosis intestinalis and pneumoperitoneum secondary to treatment with lenvatinib.
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS 2024. [PMID:
39559916 DOI:
10.17235/reed.2024.10908/2024]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2024]
Abstract
Pneumatosis intestinalis is a rare disorder that can be secondary to a variety of causes among which includes oncological treatment. Most cases due to oncological treatment are reported with targeted therapy but there is growing number of cases secondary to tyrosin kinase inhibitors that includes Lenvatinib which it can be used in the treatment of hepatocarcinoma.
Collapse